Chairman and Chief Executive Officer, Troels Jordansen
Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different cellular therapy companies including Dutch IsoTis NV, Australian Clinical Cell Culture Pty Ltd and British Azellon Ltd. where he was a co-founder. Troels roles have covered sales, marketing and general management and the last 15 years as Managing Director and/or Chairman for private and public listed companies. Troels has been part of award winning management teams raising over €150 million. Troels became Chairman of Glycostem in January 2014 and CEO in July 2016.
Chief Scientific Officer, Jan Spanholtz PhD
Dr. Jan Spanholtz initiated Glycostem's research in the start-up phase in 2007 and is currently Chief Scientific Officer (CSO) of Glycostem. Dr. Jan Spanholtz has more than 15 years of expertise in research on stem cell biology and immunology at universities and within biotech companies. He is author of various peer-reviewed research articles and inventor of Glycostem's proprietary technology platform to generate oNKord® from umbilical cord blood stem cells. For Glycostem, he has set-up and managed several national and international collaborations and spearheaded clinical translational of Glycostem's NK-cell product, oNKord®. He has developed the core IP strategy for Glycostem as inventor of feeder cell free NK-cell culture method from cord blood stem cells, synthetic culture medium for NK-cells and has was also part of several other patent applications in the stem cell field.
Chief Operating Officer, Patrick Stagier
Patrick Stragier is a biochemist with more than 25 years of international operational and managerial experience in the biopharmaceutical industry, both in Europe and North America. He has worked for companies such as Solvay, DSM-Biologics, Genzyme and Lonza. From 2009, he has been working as a consultant specialized in cell therapy. He is the co-founder of MaSTherCell a Belgium based cell therapy Contract Development and Manufacturing Organization. Besides his position at Glycostem, Patrick is the VP of Operations for another biotech company focusing on liver cell based medicines headquartered in Belgium.
Regulatory Manager, Jeroen Pieper
Jeroen Pieper has over 15 years of experience in the life science and biomedical industry. Jeroen acquired his PhD in Medical and Life Science at the University Medical Centre Radboud in the Netherlands. Since then Jeroen has held senior scientist and project management position for IsoTis/Integra in the Netherlands and USA. Jeroen has published more than 20 papers in peer reviewed scientific journals. He joined Signifix as a RA/QA consultant in 2008 where he is currently employed as a Principal Regulatory Affairs Consultant.
Quality Manager, Richard van der Linden
Richard van der Linden has more than 15 years experience in biotechnology ranging from research to production including quality management and regulatory affairs. He acquired his PhD in Molecular Immunology at University of Utrecht. Commercial experience was gained as senior scientist at Crucell NV and as Director Operations CatchMabs BV working with (therapeutic) antibodies. At CatchMabs BV Richard was responsible for production/quality management and introduced GMP. He joined Signifix in 2006 where he has gained ample experience in the tissue and cells, ATMPs and Medical Devices field. He currently holds the position as senior QA/RA consultant.